J&J: positive real-life data in prostate cancer

(CercleFinance.com) - On Wednesday, Johnson & Johnson announced positive real-life data at two years for Erleada (apalutamide), its oral tablet for prostate cancer.


According to the findings, the drug delivered a 'statistically significant' overall survival benefit to treated patients at the end of 24 months.

At the end of this period, the proportion of patients alive reached 87.6%, up from 82.4% in the Phase 3 clinical trial.

These real-world data, collected from 4000 individuals, were designed to compare the efficacy of Erleada (apalutamide), an androgen receptor blocker, against enzalutamide, another oral drug, in patients with metastatic castration-sensitive prostate cancer (mCSCC).

They were presented today at the European Oncology Pharmacy Congress in Lisbon.

Copyright (c) 2024 CercleFinance.com. All rights reserved.